{"id":5340,"date":"2019-06-25T17:03:54","date_gmt":"2019-06-25T11:33:54","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=5340"},"modified":"2021-07-24T12:57:25","modified_gmt":"2021-07-24T07:27:25","slug":"pharma-market-happenings-for-gsk-erytech-pharma-krystal","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-market-happenings-for-gsk-erytech-pharma-krystal","title":{"rendered":"Zejula&#8217;s priority review; Erytech Pharma&#8217;s new facility; good news for Krystal"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\"><strong>FDA grants priority review to Zejula <\/strong><\/h4>\n\n\n\n<p><strong>Niraparib <\/strong>(Zejula) received a priority review by the U.S. FDA, in response to a supplemental New Drug Application (sNDA) submitted by Tesaro.  The drug, acquired by <strong>GlaxoSmithKline <\/strong>along with the drugmaker Tesaro for <strong>USD 5.1 Million<\/strong>, has an action date of October 24, 2019. The sNDA submitted supports new treatments for the advanced ovarian, fallopian tube, or primary peritoneal cancer patients treated with 3 or more prior chemotherapy regimens and whose cancer is associated with either BRCA mutation or homologous recombination deficiency (HRD) and who have progressed more than 6 months after the last platinum-based chemotherapy.   The current <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/epithelial-ovarian-cancer-pipeline-insight\">Ovarian cancer therapies<\/a><\/strong> include Targeted Therapy and Chemotherapy. Ovarian cancer is the 8th most common cancer among women <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/epithelial-ovarian-cancer-epidemiology-forecast\">affecting 21,000 females in the U.S<\/a>.<\/strong> <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Erytech Pharma opens up a new manufacturing facility <\/strong><\/h4>\n\n\n\n<p><strong>Erytech Pharma<\/strong>&#8211; a clinical-stage biopharmaceutical company &#8211; announced the opening of its new Princeton, NJ GMP manufacturing facility. The new facility will be fully equipped to support production capacity needs for its lead candidate <strong>Graspa <\/strong>(eryaspase). <strong>Eryaspase <\/strong>is in Phase III testing for the treatment of second-line metastatic pancreatic cancer at approximately 120 clinical sites in Europe and the United States. <strong>Pancreatic cancer<\/strong> is the fourth-leading cause of cancer death in both men and women, with an estimated 43,090 deaths in 2017. Some of the FDA-approved drugs<br>in the pancreatic cancer treatment market are Genentech\u2019s <strong>Tarceva <\/strong>(erlotinib), Ipsen\u2019s <strong>Onivyde <\/strong>(irinotecan liposome injection), <strong>Eli Lilly\u2019s Gemzar <\/strong>(gemcitabine HCL) and many more. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Krystal Biotech shares soar after gene therapy berakthrough<\/strong><\/h4>\n\n\n\n<p>Shares of <strong>Krystal Biotech <\/strong>experienced a huge boost of up to 27% after the drugmaker received an expedited review designation from the FDA for its lead drug candidate to treat a skin condition called <strong>dystrophic epidermolysis bullosa<\/strong> (DEB). Krystal announced positive results for its drug, called KB102, which is a viral vector responsible for delivering collagen directly into cells. <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/epidermolysis-bullosa-market-insights-epidemiology-and-market-forecast\">Dystrophic epidermolysis bullosa<\/a><\/strong> is a genetic condition that makes the skin very fragile and gets blistered easily. There is currently no cure for all types of Dystrophic Epidermolysis Bullosa. The treatment generally focuses on managing signs and symptoms. <\/p>\n","protected":false},"excerpt":{"rendered":"<p>FDA grants priority review to Zejula Niraparib (Zejula) received a priority review by the U.S. FDA, in response to a supplemental New Drug Application (sNDA) submitted by Tesaro. The drug, acquired by GlaxoSmithKline along with the drugmaker Tesaro for USD 5.1 Million, has an action date of October 24, 2019. The sNDA submitted supports new [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5080,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[444,3742,449],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-5340","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-ovarian-cancer","tag-ovarian-cancer-treatment","tag-pancreatic-cancer","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Zejula&#039;s priority review; Erytech Pharma&#039;s new facility<\/title>\n<meta name=\"description\" content=\"Niraparib (Zejula) received a priority review by the U.S. FDA, in response to a supplemental New Drug Application (sNDA) submitted by Tesaro...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-market-happenings-for-gsk-erytech-pharma-krystal\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zejula&#039;s priority review; Erytech Pharma&#039;s new facility\" \/>\n<meta property=\"og:description\" content=\"Niraparib (Zejula) received a priority review by the U.S. FDA, in response to a supplemental New Drug Application (sNDA) submitted by Tesaro...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-market-happenings-for-gsk-erytech-pharma-krystal\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-06-25T11:33:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09022909\/Notizia-new.png\" \/>\n\t<meta property=\"og:image:width\" content=\"647\" \/>\n\t<meta property=\"og:image:height\" content=\"345\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Zejula's priority review; Erytech Pharma's new facility","description":"Niraparib (Zejula) received a priority review by the U.S. FDA, in response to a supplemental New Drug Application (sNDA) submitted by Tesaro...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-market-happenings-for-gsk-erytech-pharma-krystal","og_locale":"en_US","og_type":"article","og_title":"Zejula's priority review; Erytech Pharma's new facility","og_description":"Niraparib (Zejula) received a priority review by the U.S. FDA, in response to a supplemental New Drug Application (sNDA) submitted by Tesaro...","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-market-happenings-for-gsk-erytech-pharma-krystal","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-06-25T11:33:54+00:00","article_modified_time":"2021-07-24T07:27:25+00:00","og_image":[{"width":647,"height":345,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09022909\/Notizia-new.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-market-happenings-for-gsk-erytech-pharma-krystal","url":"https:\/\/www.delveinsight.com\/blog\/pharma-market-happenings-for-gsk-erytech-pharma-krystal","name":"Zejula's priority review; Erytech Pharma's new facility","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-market-happenings-for-gsk-erytech-pharma-krystal#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-market-happenings-for-gsk-erytech-pharma-krystal#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09022909\/Notizia-new.png","datePublished":"2019-06-25T11:33:54+00:00","dateModified":"2021-07-24T07:27:25+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Niraparib (Zejula) received a priority review by the U.S. FDA, in response to a supplemental New Drug Application (sNDA) submitted by Tesaro...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-market-happenings-for-gsk-erytech-pharma-krystal"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-market-happenings-for-gsk-erytech-pharma-krystal#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09022909\/Notizia-new.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09022909\/Notizia-new.png","width":647,"height":345,"caption":"Recent Pharma News"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09022909\/Notizia-new-300x160.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ovarian Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ovarian Cancer Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pancreatic Cancer<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Ovarian Cancer<\/span>","<span class=\"advgb-post-tax-term\">Ovarian Cancer Treatment<\/span>","<span class=\"advgb-post-tax-term\">Pancreatic Cancer<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Jun 25, 2019","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Jun 25, 2019 5:03 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"Recent Pharma News","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5340","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=5340"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5340\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/5080"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=5340"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=5340"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=5340"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=5340"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=5340"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}